Amicus Therapeutics, Inc. (NASDAQ:FOLD)‘s stock had its “outperform” rating reiterated by research analysts at Robert W. Baird in a research report issued on Wednesday. They currently have a $18.00 target price on the biopharmaceutical company’s stock, up from their prior target price of $16.00. Robert W. Baird’s target price would suggest a potential upside of 10.84% from the stock’s previous close.

Several other research analysts have also recently issued reports on the stock. Leerink Swann reissued an “outperform” rating and set a $17.00 price target (down from $18.00) on shares of Amicus Therapeutics in a report on Saturday, September 16th. BidaskClub downgraded shares of Amicus Therapeutics from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, August 2nd. Zacks Investment Research lowered Amicus Therapeutics from a “hold” rating to a “sell” rating in a report on Wednesday, July 12th. Cowen and Company reaffirmed a “buy” rating and issued a $16.00 price objective (up previously from $10.00) on shares of Amicus Therapeutics in a report on Tuesday, July 11th. Finally, Chardan Capital reaffirmed a “buy” rating and issued a $16.50 price objective (down previously from $17.50) on shares of Amicus Therapeutics in a report on Wednesday, September 13th. Two equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. Amicus Therapeutics has a consensus rating of “Buy” and a consensus price target of $17.92.

Shares of Amicus Therapeutics (NASDAQ:FOLD) traded up 9.21% on Wednesday, hitting $16.24. The stock had a trading volume of 10,582,440 shares. The company’s market cap is $2.67 billion. Amicus Therapeutics has a one year low of $4.41 and a one year high of $16.60. The firm’s 50-day moving average is $13.82 and its 200-day moving average is $10.45.

Amicus Therapeutics (NASDAQ:FOLD) last released its earnings results on Monday, August 7th. The biopharmaceutical company reported ($0.34) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.37) by $0.03. The company had revenue of $7.16 million during the quarter, compared to analysts’ expectations of $6.96 million. Amicus Therapeutics had a negative net margin of 1,279.88% and a negative return on equity of 61.25%. During the same quarter last year, the business earned ($0.40) EPS. On average, analysts expect that Amicus Therapeutics will post ($1.31) EPS for the current fiscal year.

TRADEMARK VIOLATION WARNING: This piece was originally posted by American Banking News and is owned by of American Banking News. If you are viewing this piece on another domain, it was stolen and republished in violation of United States & international trademark & copyright law. The correct version of this piece can be accessed at https://www.americanbankingnews.com/2017/10/04/amicus-therapeutics-inc-fold-receives-outperform-rating-from-robert-w-baird.html.

In related news, major shareholder Life Sciences Maste Perceptive acquired 1,500,000 shares of the firm’s stock in a transaction that occurred on Thursday, July 13th. The shares were purchased at an average price of $12.25 per share, with a total value of $18,375,000.00. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. 3.40% of the stock is owned by company insiders.

A number of institutional investors and hedge funds have recently bought and sold shares of the business. FMR LLC boosted its position in Amicus Therapeutics by 3.4% during the second quarter. FMR LLC now owns 21,437,508 shares of the biopharmaceutical company’s stock worth $215,876,000 after purchasing an additional 705,153 shares in the last quarter. Redmile Group LLC grew its holdings in Amicus Therapeutics by 5.9% in the second quarter. Redmile Group LLC now owns 12,043,932 shares of the biopharmaceutical company’s stock valued at $121,282,000 after purchasing an additional 668,080 shares during the last quarter. Vanguard Group Inc. increased its position in shares of Amicus Therapeutics by 5.0% in the second quarter. Vanguard Group Inc. now owns 9,118,246 shares of the biopharmaceutical company’s stock valued at $91,821,000 after buying an additional 430,486 shares in the last quarter. Palo Alto Investors LLC increased its position in shares of Amicus Therapeutics by 0.7% in the second quarter. Palo Alto Investors LLC now owns 7,940,788 shares of the biopharmaceutical company’s stock valued at $79,964,000 after buying an additional 57,800 shares in the last quarter. Finally, Janus Capital Management LLC increased its position in shares of Amicus Therapeutics by 3.6% in the first quarter. Janus Capital Management LLC now owns 7,136,697 shares of the biopharmaceutical company’s stock valued at $50,883,000 after buying an additional 244,906 shares in the last quarter.

About Amicus Therapeutics

Amicus Therapeutics, Inc is a biotechnology company. The Company is engaged in the discovery, development and commercialization of a set of treatments for patients living with devastating rare and orphan diseases. Its lead product, migalastat HCl is a small molecule that can be used as a monotherapy and in combination with enzyme replacement therapy (ERT) for Fabry disease.

Analyst Recommendations for Amicus Therapeutics (NASDAQ:FOLD)

Receive News & Ratings for Amicus Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amicus Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.